Jove
Visualize
Contact Us

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

401
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
401
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

955
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
955
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

548
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
548
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

405
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

381
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
381

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.

American journal of therapeutics·2026
Same author

Edaravone Oral Suspension: A Neuroprotective Agent to Treat Amyotrophic Lateral Sclerosis.

American journal of therapeutics·2024
Same author

Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder.

American journal of therapeutics·2024
Same author

Major Drugs Shortages: Ethical Dilemma in Clinical Practice.

American journal of therapeutics·2023
Same author

Anakinra-An Interleukin-1 Receptor Antagonist for COVID-19.

American journal of therapeutics·2023
Same author

Assessment of a Mindfulness Meditation Elective in an Accelerated Doctor of Pharmacy Program.

American journal of pharmaceutical education·2022
Same journal

Pharmacists take on expanded role under new cholesterol guidelines.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Recent and anticipated novel drug approvals (Q2 2026 through Q1 2027).

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Optimizing transitions from direct factor Xa inhibitors to unfractionated heparin therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Impact of pharmacist involvement on hospital sepsis response teams.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Attributes of centralized health-system specialty pharmacy clinics: A scoping review using the Donabedian model.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same journal

Zoliflodacin: A novel single-dose oral antibiotic for uncomplicated urogenital gonorrhea.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 27, 2026

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.5K

Daptomycin use in pediatric patients.

Cheryl Durand1, Andrew Brueckner2, Chelsea Sampadian2

  • 1Cheryl Durand, Pharm.D., is Assistant Professor of Pharmacy Practice; Andrew Brueckner is a Pharm.D. candidate; Chelsea Sampadian is a Pharm.D. candidate; Kristine C. Willett, Pharm.D., is Associate Professor of Pharmacy Practice; and Paul Belliveau, Pharm.D., is Professor of Pharmacy Practice, School of Pharmacy-Worcester/Manchester, MCPHS University, Manchester, NH. cheryl.durand@mcphs.edu.

American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
|June 29, 2014
PubMed
Summary
This summary is machine-generated.

Pediatric patients may need higher daptomycin doses than adults due to faster clearance. Daptomycin is generally well-tolerated and effective for invasive infections when other options fail.

More Related Videos

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

22.2K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Related Experiment Videos

Last Updated: Apr 27, 2026

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery
06:03

Pancreatic Duct Infusion: An Effective and Selective Method of Drug and Viral Delivery

Published on: September 30, 2021

4.5K
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA

Published on: February 9, 2011

22.2K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Area of Science:

  • Pediatric Infectious Diseases
  • Pharmacokinetics and Pharmacodynamics
  • Antibiotic Therapy

Background:

  • Daptomycin is recommended for methicillin-resistant Staphylococcus aureus (MRSA) in pediatric patients, but this is based on expert opinion.
  • Limited evidence exists for pediatric daptomycin use, necessitating a review of current data.

Purpose of the Study:

  • To review and evaluate the available evidence on daptomycin use in pediatric patients.
  • To assess the safety, efficacy, and dosing requirements of daptomycin in pediatric populations.

Main Methods:

  • Literature search for pharmacokinetic studies, case reports, and retrospective reviews on pediatric daptomycin use.
  • Analysis of pharmacokinetic parameters (clearance, AUC, half-life) in pediatric patients compared to adults.
  • Review of clinical outcomes in pediatric cases treated with daptomycin.

Main Results:

  • Pediatric patients exhibit faster daptomycin clearance (CL) and a lower area under the concentration-time curve (AUC) compared to adults.
  • Daptomycin has a shorter half-life in younger children (2-6 years) than in adolescents (12-17 years).
  • A retrospective review of 16 pediatric cases showed positive outcomes with daptomycin added to standard therapy, with good tolerability.

Conclusions:

  • Higher daptomycin doses may be required in pediatric patients to achieve therapeutic serum concentrations due to faster CL and lower AUC.
  • Daptomycin use in pediatrics should be reserved for situations where alternative treatments are not feasible due to toxicity, resistance, or expected failure.
  • Further research is needed to establish optimal pediatric dosing regimens for daptomycin.